Ireland - English - HPRA (Health Products Regulatory Authority)

teva b.v. - teriparatide - solution for injection in pre-filled pen - 20/80 - parathyroid hormones and analogues; teriparatide

Ireland - English - HPRA (Health Products Regulatory Authority)

teva b.v. - teriparatide - solution for injection in pre-filled pen - 20/80 - parathyroid hormones and analogues; teriparatide

European Union - English - EMA (European Medicines Agency)

stada arzneimittel ag - teriparatide - osteoporosis - calcium homeostasis - movymia is indicated in adults.treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. in postmenopausal women, a significant reduction in the incidence of vertebral and non vertebral fractures but not hip fractures has been demonstrated.treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.

European Union - English - EMA (European Medicines Agency)

gedeon richter plc. - teriparatide - osteoporosis - calcium homeostasis - terrosa is indicated in adults.treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. in postmenopausal women, a significant reduction in the incidence of vertebral and non vertebral fractures but not hip fractures has been demonstrated.treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.

European Union - English - EMA (European Medicines Agency)

eurogenerics holdings b.v. - teriparatide - osteoporosis - calcium homeostasis - qutavina is indicated in adults.treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated.treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.

European Union - English - EMA (European Medicines Agency)

theramex ireland limited - teriparatide - osteoporosis - calcium homeostasis - livogiva is indicated in adults.treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated.treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.

European Union - English - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriparatide - osteoporosis - calcium homeostasis - sondelbay is indicated in adults.treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated.treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.

European Union - English - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - teriparatide - osteoporosis; osteoporosis, postmenopausal - calcium homeostasis - teriparatide sun is indicated in adults.treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5.1). in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated.treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.1).

European Union - English - EMA (European Medicines Agency)

strides pharma (cyprus) limited - teriparatide - osteoporosis; osteoporosis, postmenopausal - calcium homeostasis - kauliv is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5.1). in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.1).,

European Union - English - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - parathyroid hormone - hypoparathyroidism - calcium homeostasis - natpar is indicated as adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.